Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment. Never before was there a drug that actually worked for weight loss.

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

If you suffered a loss in Novo Nordisk you have until March 25, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve ...

Novo Nordisk's head of development, pointed out that only 57% of patients had received the highest dose of CagriSema, asserting that the company remains "encouraged by the weight-loss profile of ...

with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a 25% loss. At the least, the new 7.2mg results point to scope for hiking the ...